

MURAE ORGANISOR LIMITED

(Formerly known as Earum Pharmaceuticals Limited)

CIN: L24230GJ2012PLC071299

Regd. Office: A-1311, Sun West Bank, Ashram Road, Ashram Road P.O, Ahmedabad,
Ahmedabad City, Gujarat – 380009

E-mail: earumpharma@gmail.com Website: www.earumpharma.com

Date: 15th October, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held today i.e., 15th October, 2024

Ref: Security Id: MURAE/ Code: 542724

Pursuant to second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors in their meeting held today i.e. Tuesday, 15th October, 2024 at the Registered Office of the Company situated at A-1311, Sun West Bank, Ashram Road, Ashram Road P.O, Ahmedabad, Gujarat – 380009 which commenced at 4:00 P.M. and concluded at 5:00 P.M. inter-alia has considered and approved:

1. Increase in Authorised Share Capital and Alteration of the Capital clause in Memorandum of Association of the Company upto Rs. 190.00 Crores by alteration of the capital clause in the Memorandum of Association of the Company subject to the approval of Shareholders in General Meeting.
2. Issue of [•] Equity Shares of face value of Rs. 2.00/- each for cash at an Issue Price of Rs. [•] per Equity Share aggregating upto Rs. 50.00 Crores to all the eligible equity shareholders of the Company as on the Record date (*to be determined by the Board in due course*) on Rights basis (**'Rights Issue'**). The brief term of Rights Issue is approved by the Board is attached herewith as **Annexure – I**.
3. The formation of a committee of Directors to decide the matters relating to the Rights Issue (**'Rights Issue Committee'**) which includes, inter alia, to decide or alter the treatment to be given to fractional entitlements, if any to make any applications to the Regulatory authorities as may be required, determine the terms and conditions of the Rights Issue including structure and timing of the issue.
4. The decision to hold Extra-Ordinary General Meeting (EGM) for approval of the shareholders along with EGM notice and other relevant documents shall be submitted in due course.

Kindly take note of the same and oblige.

For, Murae Organisor Limited
(Formerly known as Earum Pharmaceuticals Limited)

Manthan Rameshbhai Tilva
Managing Director
DIN: 10453462

MURAE ORGANISOR LIMITED

(Formerly known as Earum Pharmaceuticals Limited)

CIN: L24230GJ2012PLC071299

Regd. Office: A-1311, Sun West Bank, Ashram Road, Ashram Road P.O, Ahmedabad,
Ahmedabad City, Gujarat – 380009

E-mail: earumpharma@gmail.com Website: www.earumpharma.com

Annexure – I

Sr. No.	Particulars	Details**
1.	Details of the securities	Equity shares of Rs. 2.00/- each
2.	Type of issue	Rights issue of equity shares
3.	Equity shares offered through the issue	[•] Equity Shares*
4.	Face value per equity share	Rs. 2.00/-
5.	Issue price per equity share	Rs. [•]
6.	Rights entitlement ratio	[•] Rights Equity share for every [•] fully paid-up Equity shares held by the Eligible Equity shareholders in the Company as on Record date (to be determined by Board of Directors in due course)
7.	Outstanding equity shares before Rights Issue	69,71,11,616 Equity shares of Rs. 2.00/- each
8.	Outstanding equity shares post Rights Issue (assuming fully subscription)	[•] Equity shares of Rs. 2.00/- each
9.	Terms of Payment	Full amount of Rs. [•] per Equity share is payable on application by Eligible Equity shareholders

*Equity shares which are offered through the rights issue are maximum no. of shares that will be issued.

**Details pertaining to Issue structure i.e. Issue price, offered shares, Rights entitlement ratio etc. shall be disclosed in Final Letter of Offer.

The detailed terms of the Rights Issue including the procedure for the Rights Issue will be specified in the Letter of Offer which will be sent by the Company to the Eligible Equity Shareholders holding Equity Shares of the Company as on the Record Date in due course.